Latest news with #Biegler
Business Insider
08-08-2025
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX) and Relay Therapeutics (RLAY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX – Research Report) and Relay Therapeutics (RLAY – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. OptimizeRx (OPRX) In a report released yesterday, Richard Baldry from Roth MKM reiterated a Buy rating on OptimizeRx, with a price target of $27.00. The company's shares closed last Thursday at $12.84, close to its 52-week high of $14.13. According to Baldry is a 5-star analyst with an average return of 17.4% and a 58.6% success rate. Baldry covers the Technology sector, focusing on stocks such as Zeta Global Holdings Corp, FiscalNote Holdings, and Research Solutions. Currently, the analyst consensus on OptimizeRx is a Strong Buy with an average price target of $17.80, representing a 39.7% upside. In a report issued on August 4, Lake Street also maintained a Buy rating on the stock with a $19.00 price target. Relay Therapeutics (RLAY) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Relay Therapeutics yesterday. The company's shares closed last Thursday at $3.49, close to its 52-week low of $2.69. According to Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 31.9% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.20, which is a 240.8% upside from current levels. In a report issued on August 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $3.50 price target.
Business Insider
16-06-2025
- Business
- Business Insider
Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) yesterday and set a price target of $32.00. The company's shares closed last Friday at $11.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -12.1% and a 31.68% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and Nurix Therapeutics. In addition to Oppenheimer, Nurix Therapeutics also received a Buy from Truist Financial's Srikripa Devarakonda in a report issued on June 13. However, on June 3, Leerink Partners reiterated a Hold rating on Nurix Therapeutics (NASDAQ: NRIX).
Business Insider
02-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Bristol-Myers Squibb (BMY)
Analysts fell to the sidelines weighing in on Arvinas Holding Company (ARVN – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Arvinas Holding Company (ARVN) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Arvinas Holding Company yesterday. The company's shares closed last Friday at $7.20. According to Biegler 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $14.66 average price target, implying a 95.5% upside from current levels. In a report released yesterday, Leerink Partners also downgraded the stock to Hold with a $9.00 price target. Bristol-Myers Squibb (BMY) Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb on May 31. The company's shares closed last Friday at $48.28. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Eli Lilly & Co. The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $55.53 average price target, representing a 16.0% upside. In a report issued on May 16, BMO Capital also maintained a Hold rating on the stock with a $53.00 price target.
Business Insider
02-06-2025
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Gilead Sciences (GILD – Research Report). Confident Investing Starts Here: AbbVie (ABBV) In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on AbbVie. The company's shares closed last Friday at $186.11. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $212.13, implying a 14.7% upside from current levels. In a report issued on May 30, Berenberg Bank also maintained a Hold rating on the stock with a $170.00 price target. Gilead Sciences (GILD) In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences, with a price target of $125.00. The company's shares closed last Friday at $110.08. According to Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $120.47, implying a 7.9% upside from current levels. In a report issued on May 21, Jefferies also maintained a Buy rating on the stock with a $130.00 price target.
Business Insider
15-05-2025
- Business
- Business Insider
Oppenheimer Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a price target of $9.00. The company's shares closed yesterday at $1.14. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -16.2% and a 27.06% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and IDEAYA Biosciences. Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $11.43. ACRV market cap is currently $37.63M and has a P/E ratio of -0.46. Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRV in relation to earlier this year.
